140 related articles for article (PubMed ID: 20919529)
1. The role of PET scanning in pancreatic cancer.
Serrano OK; Chaudhry MA; Leach SD
Adv Surg; 2010; 44():313-25. PubMed ID: 20919529
[TBL] [Abstract][Full Text] [Related]
2. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
[TBL] [Abstract][Full Text] [Related]
3. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
4. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
5. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
[TBL] [Abstract][Full Text] [Related]
6. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
[TBL] [Abstract][Full Text] [Related]
7. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
8. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.
Pergolini I; Crippa S; Salgarello M; Belfiori G; Partelli S; Ruffo G; Pucci A; Zamboni G; Falconi M
Dig Liver Dis; 2018 Jan; 50(1):84-90. PubMed ID: 29017830
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
Lytras D; Connor S; Bosonnet L; Jayan R; Evans J; Hughes M; Garvey CJ; Ghaneh P; Sutton R; Vinjamuri S; Neoptolemos JP
Dig Surg; 2005; 22(1-2):55-61; discussion 62. PubMed ID: 15838173
[TBL] [Abstract][Full Text] [Related]
10. PET and PET/CT for pancreatic malignancies.
Delbeke D; Martin WH
Surg Oncol Clin N Am; 2010 Apr; 19(2):235-54. PubMed ID: 20159513
[TBL] [Abstract][Full Text] [Related]
11. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
12. [18FDG-PET imaging of pancreatic adenocarcinoma].
Daenen F; Hustinx R; Belhocine T; Focan C; Honoré P; Rigo P
Rev Med Liege; 2000 Feb; 55(2):89-94. PubMed ID: 10769575
[TBL] [Abstract][Full Text] [Related]
13. Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.
Chong JU; Hwang HK; Lee JH; Yun M; Kang CM; Lee WJ
PLoS One; 2017; 12(2):e0172606. PubMed ID: 28235029
[TBL] [Abstract][Full Text] [Related]
14. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
[TBL] [Abstract][Full Text] [Related]
15. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
16. THE USE OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY TO ASSESS CLINICAL OUTCOMES OF PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC CANCER.
Durmus A; Yilmaz A; Malya F; Ozturk G; Bektasoglu H; Ertugrul G; Karyagar S; Karatepe O
Georgian Med News; 2016 Apr; (253):26-9. PubMed ID: 27249430
[TBL] [Abstract][Full Text] [Related]
17. Is positron emission tomography using 18F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses?
Rasmussen I; Sörensen J; Långström B; Haglund U
Scand J Surg; 2004; 93(3):191-7. PubMed ID: 15544073
[TBL] [Abstract][Full Text] [Related]
18. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pancreatic carcinoma with FDG PET.
Jadvar H; Fischman AJ
Abdom Imaging; 2001; 26(3):254-9. PubMed ID: 11429948
[TBL] [Abstract][Full Text] [Related]
20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]